uniQure (NASDAQ:QURE) Given Consensus Rating of “Buy” by Analysts

uniQure (NASDAQ:QURE) has earned a consensus recommendation of “Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $32.14.

A number of equities research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating on shares of uniQure in a report on Wednesday. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday, December 10th. Leerink Partners lifted their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Royal Bank of Canada increased their price target on shares of uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. abrdn plc increased its stake in uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after purchasing an additional 1,528,581 shares during the period. Franklin Resources Inc. purchased a new position in shares of uniQure in the third quarter worth $7,360,000. Point72 Asset Management L.P. raised its holdings in uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after buying an additional 752,889 shares during the last quarter. FMR LLC boosted its position in uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after buying an additional 346,274 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in uniQure during the 2nd quarter valued at $815,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ QURE opened at $15.40 on Friday. The stock has a fifty day simple moving average of $7.04 and a two-hundred day simple moving average of $6.36. uniQure has a 1-year low of $3.73 and a 1-year high of $17.39. The firm has a market cap of $750.60 million, a price-to-earnings ratio of -3.10 and a beta of 0.89. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Analysts anticipate that uniQure will post -3.81 earnings per share for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.